

Kenneth P Nephew

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8230532/publications.pdf>

Version: 2024-02-01

118
papers

9,341
citations

47006

47
h-index

39675

94
g-index

127
all docs

127
docs citations

127
times ranked

13381
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors. <i>Cancer Research</i> , 2008, 68, 4311-4320.	0.9	1,196
2	Rethinking ovarian cancer: recommendations for improving outcomes. <i>Nature Reviews Cancer</i> , 2011, 11, 719-725.	28.4	1,084
3	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 668-679.	28.4	839
4	Epigenetic Resensitization to Platinum in Ovarian Cancer. <i>Cancer Research</i> , 2012, 72, 2197-2205.	0.9	344
5	MicroRNA Cluster 221-222 and Estrogen Receptor β Interactions in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2010, 102, 706-721.	6.3	301
6	Diverse Gene Expression and DNA Methylation Profiles Correlate with Differential Adaptation of Breast Cancer Cells to the Antiestrogens Tamoxifen and Fulvestrant. <i>Cancer Research</i> , 2006, 66, 11954-11966.	0.9	226
7	Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. <i>BMC Medical Genomics</i> , 2009, 2, 34.	1.5	192
8	Epigenetic gene silencing in cancer initiation and progression. <i>Cancer Letters</i> , 2003, 190, 125-133.	7.2	167
9	The epigenetics of ovarian cancer drug resistance and resensitization. <i>American Journal of Obstetrics and Gynecology</i> , 2004, 191, 1552-1572.	1.3	156
10	Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. <i>Clinical Cancer Research</i> , 2002, 8, 2246-52.	7.0	156
11	MicroRNA and mRNA integrated analysis (MMIA): a web tool for examining biological functions of microRNA expression. <i>Nucleic Acids Research</i> , 2009, 37, W356-W362.	14.5	149
12	In vivo tumor growth of high-grade serous ovarian cancer cell lines. <i>Gynecologic Oncology</i> , 2015, 138, 372-377.	1.4	149
13	Prognostic DNA Methylation Biomarkers in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 2788-2794.	7.0	148
14	A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. <i>Cancer</i> , 2010, 116, 4043-4053.	4.1	139
15	Minireview: Epigenetic Changes in Ovarian Cancer. <i>Endocrinology</i> , 2009, 150, 4003-4011.	2.8	136
16	TGF- β 2 induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells. <i>Epigenetics</i> , 2014, 9, 1461-1472.	2.7	136
17	Epigenetic Targeting of Ovarian Cancer Stem Cells. <i>Cancer Research</i> , 2014, 74, 4922-4936.	0.9	136
18	Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1505-1514.	4.1	133

#	ARTICLE	IF	CITATIONS
19	Hypermethylation of the TGF- β 2 target, ABCA1 is associated with poor prognosis in ovarian cancer patients. <i>Clinical Epigenetics</i> , 2015, 7, 1.	4.1	133
20	Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance. <i>Bioinformatics</i> , 2009, 25, 430-434.	4.1	129
21	The NEDD8 Pathway Is Required for Proteasome-Mediated Degradation of Human Estrogen Receptor (ER)- β and Essential for the Antiproliferative Activity of ICI 182,780 in ER β -Positive Breast Cancer Cells. <i>Molecular Endocrinology</i> , 2003, 17, 356-365.	3.7	120
22	Therapeutic targeting using tumor specific peptides inhibits long non-coding RNA HOTAIR activity in ovarian and breast cancer. <i>Scientific Reports</i> , 2017, 7, 894.	3.3	110
23	Dominant-Negative Histone H3 Lysine 27 Mutant Derepresses Silenced Tumor Suppressor Genes and Reverses the Drug-Resistant Phenotype in Cancer Cells. <i>Cancer Research</i> , 2006, 66, 5582-5591.	0.9	102
24	Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2010, 116, 195-201.	1.4	95
25	An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations. <i>Clinical Cancer Research</i> , 2018, 24, 3163-3175.	7.0	93
26	Effect of Estradiol on Estrogen Receptor Expression in Rat Uterine Cell Types1. <i>Biology of Reproduction</i> , 2000, 62, 168-177.	2.7	91
27	Definition of a FoxA1 Cistrome That Is Crucial for G1 to S-Phase Cell-Cycle Transit in Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2011, 71, 6738-6748.	0.9	87
28	The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer. <i>Clinical Cancer Research</i> , 2014, 20, 6504-6516.	7.0	87
29	Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer. <i>Oncotarget</i> , 2015, 6, 16638-16652.	1.8	86
30	Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs. <i>Cancer Research</i> , 2018, 78, 631-644.	0.9	86
31	IL-6 mediates platinum-induced enrichment of ovarian cancer stem cells. <i>JCI Insight</i> , 2018, 3, .	5.0	83
32	Inhibiting Proteasomal Proteolysis Sustains Estrogen Receptor- β Activation. <i>Molecular Endocrinology</i> , 2004, 18, 2603-2615.	3.7	78
33	Agonist and antagonist switch <sc>DNA</sc> motifs recognized by human androgen receptor in prostate cancer. <i>EMBO Journal</i> , 2015, 34, 502-516.	7.8	74
34	MiR-373 targeting of the Rab22a oncogene suppresses tumor invasion and metastasis in ovarian cancer. <i>Oncotarget</i> , 2014, 5, 12291-12303.	1.8	69
35	New anti-cancer strategies: Epigenetic therapies and biomarkers. <i>Frontiers in Bioscience - Landmark</i> , 2005, 10, 1897.	3.0	66
36	A new method for stranded whole transcriptome RNA-seq. <i>Methods</i> , 2013, 63, 126-134.	3.8	59

#	ARTICLE	IF	CITATIONS
37	Long-range regulators of the lncRNA <i>HOTAIR</i> enhance its prognostic potential in breast cancer. <i>Human Molecular Genetics</i> , 2016, 25, 3269-3283.	2.9	58
38	Functional characterization of a panel of high-grade serous ovarian cancer cell lines as representative experimental models of the disease. <i>Oncotarget</i> , 2016, 7, 32810-32820.	1.8	58
39	EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells. <i>Oncotarget</i> , 2016, 7, 84453-84467.	1.8	57
40	Hypomethylation signature of tumor-initiating cells predicts poor prognosis of ovarian cancer patients. <i>Human Molecular Genetics</i> , 2014, 23, 1894-1906.	2.9	56
41	A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1009-1016.	7.0	56
42	MicroRNA-335 and -33p synergize to inhibit estrogen receptor alpha expression and promote tamoxifen resistance. <i>FEBS Letters</i> , 2017, 591, 382-392.	2.8	52
43	Multivalent epigenetic marks confer microenvironment-responsive epigenetic plasticity to ovarian cancer cells. <i>Epigenetics</i> , 2010, 5, 716-729.	2.7	51
44	A Rationally Designed Histone Deacetylase Inhibitor with Distinct Antitumor Activity against Ovarian Cancer. <i>Neoplasia</i> , 2009, 11, 552-IN9.	5.3	50
45	A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses. <i>Clinical Cancer Research</i> , 2018, 24, 2285-2293.	7.0	49
46	Epigenetic Crosstalk between the Tumor Microenvironment and Ovarian Cancer Cells: A Therapeutic Road Less Traveled. <i>Cancers</i> , 2018, 10, 295.	3.7	49
47	Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study. <i>PLoS ONE</i> , 2015, 10, e0141279.	2.5	49
48	Studies of dehydroepiandrosterone (DHEA) with the human estrogen receptor in yeast. <i>Molecular and Cellular Endocrinology</i> , 1998, 143, 133-142.	3.2	47
49	The Activating Enzyme of NEDD8 Inhibits Steroid Receptor Function. <i>Molecular Endocrinology</i> , 2002, 16, 315-330.	3.7	47
50	Cell-Specific Induction of c-fos Expression in the Pituitary Gland by Estrogen*. <i>Endocrinology</i> , 1997, 138, 2128-2135.	2.8	47
51	Role of epigenomics in ovarian and endometrial cancers. <i>Epigenomics</i> , 2010, 2, 419-447.	2.1	46
52	Ovarian Cancer Stem Cells: Role in Metastasis and Opportunity for Therapeutic Targeting. <i>Cancers</i> , 2019, 11, 934.	3.7	45
53	Glutamine Metabolism Drives Growth in Advanced Hormone Receptor Positive Breast Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 686.	2.8	41
54	Decitabine reactivated pathways in platinum resistant ovarian cancer. <i>Oncotarget</i> , 2014, 5, 3579-3589.	1.8	41

#	ARTICLE	IF	CITATIONS
55	Expression of Estrogen Receptor Coactivators in the Rat Uterus1. <i>Biology of Reproduction</i> , 2000, 63, 361-367.	2.7	40
56	Targeting Aldehyde Dehydrogenases to Eliminate Cancer Stem Cells in Gynecologic Malignancies. <i>Cancers</i> , 2020, 12, 961.	3.7	39
57	Effects of the Xenoestrogen Bisphenol a on Expression of Vascular Endothelial Growth Factor (VEGF) in the Rat. <i>Experimental Biology and Medicine</i> , 2001, 226, 477-483.	2.4	38
58	BioVLAB-MMIA-NGS: microRNAâ€mRNA integrated analysis using high-throughput sequencing data. <i>Bioinformatics</i> , 2015, 31, 265-267.	4.1	38
59	Epigenetic Attire in Ovarian Cancer: The Emperor's New Clothes. <i>Cancer Research</i> , 2020, 80, 3775-3785.	0.9	38
60	EZH2-Mediated Downregulation of the Tumor Suppressor DAB2IP Maintains Ovarian Cancer Stem Cells. <i>Cancer Research</i> , 2020, 80, 4371-4385.	0.9	37
61	Elevated expression of long intergenic nonâ€coding RNA HOTAIR in a basalâ€like variant of MCFâ€7 breast cancer cells. <i>Molecular Carcinogenesis</i> , 2015, 54, 1656-1667.	2.7	35
62	Altered Death Receptor Signaling Promotes Epithelial-to-Mesenchymal Transition and Acquired Chemoresistance. <i>Scientific Reports</i> , 2012, 2, 539.	3.3	32
63	Targeting progesterone signaling prevents metastatic ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 31993-32004.	7.1	29
64	In vivoÂ modeling of metastatic human high-grade serous ovarian cancer in mice. <i>PLoS Genetics</i> , 2020, 16, e1008808.	3.5	27
65	The novel ZIP4 regulation and its role in ovarian cancer. <i>Oncotarget</i> , 2017, 8, 90090-90107.	1.8	27
66	Role of Neurofilament Light Polypeptide in Head and Neck Cancer Chemoresistance. <i>Molecular Cancer Research</i> , 2012, 10, 305-315.	3.4	26
67	BioVLAB-MMIA: A Cloud Environment for microRNA and mRNA Integrated Analysis (MMIA) on Amazon EC2. <i>IEEE Transactions on Nanobioscience</i> , 2012, 11, 266-272.	3.3	24
68	Epigenetic Targeting Therapies to Overcome Chemotherapy Resistance. <i>Advances in Experimental Medicine and Biology</i> , 2013, 754, 285-311.	1.6	23
69	A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer. <i>Cancer Medicine</i> , 2021, 10, 156-163.	2.8	23
70	Experimental competition induces immediate and lasting effects on the neurogenome in free-living female birds. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	23
71	Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials. <i>Oncotarget</i> , 2017, 8, 84579-84594.	1.8	23
72	Platinum-induced mitochondrial OXPHOS contributes to cancer stem cell enrichment in ovarian cancer. <i>Journal of Translational Medicine</i> , 2022, 20, .	4.4	23

#	ARTICLE	IF	CITATIONS
73	An integrative analysis of cellular contexts, miRNAs and mRNAs reveals network clusters associated with antiestrogen-resistant breast cancer cells. <i>BMC Genomics</i> , 2012, 13, 732.	2.8	22
74	Effects of Oral Administration of Tamoxifen, Toremifene, Dehydroepiandrosterone, and Vorozole on Uterine Histomorphology in the Rat. <i>Proceedings of the Society for Experimental Biology and Medicine</i> , 2000, 223, 288-294.	1.8	22
75	Interferon- β signaling is associated with BRCA1 loss-of-function mutations in high grade serous ovarian cancer. <i>Npj Precision Oncology</i> , 2019, 3, 32.	5.4	21
76	Hypermethylation and global remodelling of DNA methylation is associated with acquired cisplatin resistance in testicular germ cell tumours. <i>Epigenetics</i> , 2021, 16, 1071-1084.	2.7	21
77	Immunohistochemical detection of estrogen receptor alpha in male rat spinal cord during development. <i>Journal of Neuroscience Research</i> , 2000, 61, 329-337.	2.9	20
78	Profiling Cell-Matrix Adhesion Using Digitalized Acoustic Streaming. <i>Analytical Chemistry</i> , 2020, 92, 2283-2290.	6.5	20
79	Protein kinase A-mediated phosphorylation regulates STAT3 activation and oncogenic EZH2 activity. <i>Oncogene</i> , 2018, 37, 3589-3600.	5.9	18
80	Epigenetic Targeting of Adipocytes Inhibits High-Grade Serous Ovarian Cancer Cell Migration and Invasion. <i>Molecular Cancer Research</i> , 2018, 16, 1226-1240.	3.4	17
81	Mg ²⁺ Effect on Argonaute and RNA Duplex by Molecular Dynamics and Bioinformatics Implications. <i>PLoS ONE</i> , 2014, 9, e109745.	2.5	16
82	The role of chromatin, microRNAs, and tumor stem cells in ovarian cancer. <i>Cancer Biomarkers</i> , 2011, 8, 203-221.	1.7	15
83	Targeting Ovarian Cancer Stem Cells by Dual Inhibition of HOTAIR and DNA Methylation. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1092-1101.	4.1	15
84	A Mathematical Model of Bimodal Epigenetic Control of miR-193a in Ovarian Cancer Stem Cells. <i>PLoS ONE</i> , 2014, 9, e116050.	2.5	14
85	The Ratio of Toxic-to-Nontoxic miRNAs Predicts Platinum Sensitivity in Ovarian Cancer. <i>Cancer Research</i> , 2021, 81, 3985-4000.	0.9	14
86	Aberrant epigenetic and transcriptional events associated with breast cancer risk. <i>Clinical Epigenetics</i> , 2022, 14, 21.	4.1	14
87	The Tumor Microenvironment of High Grade Serous Ovarian Cancer. <i>Cancers</i> , 2019, 11, 21.	3.7	13
88	ERK5 Is Required for Tumor Growth and Maintenance Through Regulation of the Extracellular Matrix in Triple Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1164.	2.8	13
89	Methyl Group Acceptance Assay for the Determination of Global DNA Methylation Levels. <i>Methods in Molecular Biology</i> , 2009, 507, 35-41.	0.9	13
90	Strain differences in tamoxifen sensitivity of Sprague-Dawley and Fischer 344 rats. <i>Anti-Cancer Drugs</i> , 2002, 13, 939-947.	1.4	12

#	ARTICLE	IF	CITATIONS
91	Dose-dependent effects of 4-hydroxytamoxifen, the active metabolite of tamoxifen, on estrogen receptor-?? expression in the rat uterus. <i>Anti-Cancer Drugs</i> , 2005, 16, 559-567.	1.4	12
92	Subtype-specific CpG island shore methylation and mutation patterns in 30 breast cancer cell lines. <i>BMC Systems Biology</i> , 2016, 10, 116.	3.0	12
93	Regulation of cellular sterol homeostasis by the oxygen responsive noncoding RNA lincNORS. <i>Nature Communications</i> , 2020, 11, 4755.	12.8	12
94	Argonaute 2 Expression Correlates with a Luminal B Breast Cancer Subtype and Induces Estrogen Receptor Alpha Isoform Variation. <i>Non-coding RNA</i> , 2016, 2, 8.	2.6	11
95	Estrogen receptor-alpha-interacting cytokeratins potentiate the antiestrogenic activity of fulvestrant. <i>Cancer Biology and Therapy</i> , 2010, 9, 389-396.	3.4	10
96	Epigenetics and Ovarian Cancer. <i>Cancer Treatment and Research</i> , 2009, 149, 131-146.	0.5	9
97	Bisphenol A alters the self-renewal and differentiation capacity of human bone-marrow-derived mesenchymal stem cells. <i>Endocrine Disruptors (Austin, Tex)</i> , 2016, 4, e1200344.	1.1	9
98	Poly-ADP-Ribosylation of Estrogen Receptor-Alpha by PARP1 Mediates Antiestrogen Resistance in Human Breast Cancer Cells. <i>Cancers</i> , 2019, 11, 43.	3.7	9
99	Platinum-Induced Ubiquitination of Phosphorylated H2AX by RING1A Is Mediated by Replication Protein A in Ovarian Cancer. <i>Molecular Cancer Research</i> , 2020, 18, 1699-1710.	3.4	9
100	Changes in mRNA/protein expression and signaling pathways in in vivo passaged mouse ovarian cancer cells. <i>PLoS ONE</i> , 2018, 13, e0197404.	2.5	8
101	Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1369-1378.	6.3	8
102	Stranded Whole Transcriptome RNA-seq for All RNA Types. <i>Current Protocols in Human Genetics</i> , 2015, 84, 11.14.1-11.14.23.	3.5	7
103	Adenoviral-delivered HE4-HSV-tk sensitizes ovarian cancer cells to ganciclovir. <i>Gene Therapy and Molecular Biology</i> , 2013, 15, 120-130.	1.3	6
104	A Novel ALDH1A1 Inhibitor Blocks Platinum-Induced Senescence and Stemness in Ovarian Cancer. <i>Cancers</i> , 2022, 14, 3437.	3.7	6
105	BioVLAB-mCpG-SNP- EXPRESS : A system for multi-level and multi-perspective analysis and exploration of DNA methylation, sequence variation (SNPs), and gene expression from multi-omics data. <i>Methods</i> , 2016, 111, 64-71.	3.8	5
106	Incorporating DNA Methyltransferase Inhibitors (DNMTis) in the Treatment of Genitourinary Malignancies: A Systematic Review. <i>Targeted Oncology</i> , 2018, 13, 49-60.	3.6	5
107	ZEB2 regulates endocrine therapy sensitivity and metastasis in luminal a breast cancer cells through a non-canonical mechanism. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 25-37.	2.5	4
108	Effects of Oral Administration of Tamoxifen, Toremifene, Dehydroepiandrosterone, and Vorozole on Uterine Histomorphology in the Rat. <i>Proceedings of the Society for Experimental Biology and Medicine</i> , 2000, 223, 288-294.	1.8	3

#	ARTICLE	IF	CITATIONS
109	Complete Transcriptome RNA-Seq. <i>Methods in Molecular Biology</i> , 2017, 1513, 141-162.	0.9	2
110	Turning Up the Heat on the Pancreatic Tumor Microenvironment by Epigenetic Priming. <i>Cancer Research</i> , 2020, 80, 4610-4611.	0.9	2
111	An ERα/modulator regulatory network in the breast cancer cells. , 2011, , .		1
112	Empirical bayes model comparisons for differential methylation analysis. , 2011, , .		1
113	3D culture adds an extra dimension to targeted epigenetic therapies. <i>Cell Cycle</i> , 2013, 12, 2173-2174.	2.6	1
114	Abstract A57: Platinum induces IL-6-signaling mediated activation of ALDH1A1 and enriches the cancer stem cell population in ovarian cancer.. , 2016, , .		1
115	BioVLAB-MMIA: A Reconfigurable Cloud Computing Environment for microRNA and mRNA Integrated Analysis. , 2011, , .		0
116	A novel screening approach comparing kinase activity of small molecule inhibitors with similar molecular structures and distinct biologic effects in triple-negative breast cancer to identify targetable signaling pathways. <i>Anti-Cancer Drugs</i> , 2020, 31, 759-775.	1.4	0
117	How Epigenetic Therapy Beats Adverse Genetics in Monosomy Karyotype AML. <i>Cancer Research</i> , 2021, 81, 813-815.	0.9	0
118	Cancer Stem Cells in Ovarian Cancer. , 2011, , 151-176.		0